Mydecine Announces Partnership with LeadGen Labs
Mydecine Announces Partnership with LeadGen Labs

Mydecine Announces Partnership with LeadGen Labs

DENVER, May 05, 2021 ( GLOBE NEWSWIRE ) — Mydecine Innovations Group ( NEO : MYCO ) ( OTC : MYCOF ) ( FSE : 0NFA ) ( “ Mydecine ” or the “ Company ’ ), an emerging biopharma and life sciences ship’s company committed to the research, development, and acceptance of option nature-sourced medicine for mainstream practice, has announced a partnership with LeadGen Labs, a customs deduction and contract research organization, to support Mydecine ’ s fresh psychedelic drug development efforts and increase the number of novel molecules the Company can synthesize concurrently.
Following the announcement of the Company ’ s four initial drug candidates, Mydecine and LeadGen Labs will work to synthesize novel psychedelic molecules. LeadGen Labs, a full-service compress research administration, providing expertness in custom synthesis and route design, will work with the Mydecine research and drug design team to target these novel molecular entities and enhanced formulations, including effective dosages and safety. “ We are experiencing a renaissance of checkup interest in the classical psychedelics and Mydecine is working to iteratively improve and better understand the potential curative benefits of these known and unknown molecules, ” said Rob Roscow, Mydecine Chief Science Officer. “ We are excited to begin output on these novel patent pending molecules that hold the predict of improving the curative use of psychedelics through enhanced condom and dose control. additionally, the initial batch of fresh molecules we will inquiry represent good the first of numerous families of molecules, representing potentially dozens of patentable compounds. ” “ Complementary to Mydecine ’ s work with the University of Alberta and Applied Pharmaceutical Innovation ( API ), the partnership with LeadGen Labs expands our existing research infrastructure and allows for more rapid scale of Mydecine ’ randomness drug development pipeline and patent strategy, ” added Josh Bartch, CEO of Mydecine. “ With the ability to swiftly synthesize and analyze these versatile families of fresh molecules through both partnerships, we are in a hard position to support the latter stages of our drug growth grapevine and build upon our cerebral property portfolio that is focused on building upon the value presently present in lifelike molecules with patentable guard features that will enhance therapy, reduce anxiety and maximize delivery mechanism. ”

READ MORE  Solar System Planets Galaxy Bracelet

Reading: Mydecine Announces Partnership with LeadGen Labs

About Mydecine Innovations Group
Mydecine Innovations Group™ ( NEO : MYCO ) ( OTC : MYCOF ) ( FSE:0NFA ) is an emerging biotechnology and life sciences caller dedicated to developing and commercializing advanced solutions for treating mental health problems and enhancing life force. The company ’ s world-renowned medical and scientific advisory board is building out a robust R & D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacture adeptness with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine besides operates out of a state-of-the-art mycology lab in Denver, CO to focus on familial research for scaling commercial polish of rare ( non-psychedelic ) medicative mushrooms. At the heart of Mydecine ’ s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the aesculapian residential district with many of the populace ’ mho best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the province associated with psychedelic-assisted therapy and will continue to position itself as a long-run leader across the spectrum of clinical trials, research, engineering, and ball-shaped supply. Mydecine has besides successfully completed multiple acquisitions since its origin. Learn more at : hypertext transfer protocol : //www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

For more information, please contact: Media Contacts
Anne Donohoe / Nick Opich
KCSA Strategic Communications
myco @ kcsa.com
1-212-896-1265 / 1-212-896-1206 Investor Contacts
Charles Lee, Investor Relations
corporation @ mydecineinc.com
1-720-277-9879

Allison Soss / Erika Kay
KCSA Strategic Communications
myco @ kcsa.com
1-212-896-1267

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer contact @ mydecineinc.com For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com . This news secrete contains advanced information within the mean of canadian securities laws regarding the Company and its clientele, which relate to future events or future performance and reflect management ’ south current expectations and assumptions. Often but not constantly, advanced information can be identified by the use of words such as “ expect ”, “ intends ”, “ anticipated ”, “ believes ” or variations ( including negative variations ) of such words and phrases, or state that certain actions, events or results “ may ”, “ could ”, “ would ” or “ will ” be taken, occur or be achieved. such advanced statements reflect management ’ s current beliefs and are based on assumptions made by and information presently available to the Company. Readers are cautioned that these advanced statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the handiness and continuity of finance, the ability of the Company to adequately protect and enforce its intellectual property, the Company ‘s ability to bring its products to commercial production, continued growth of the global adaptive nerve pathway medicine, lifelike health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the exploitation, production, sale and use of the Company ‘s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in advanced information, there may be other factors that cause results not to be as anticipate, estimated or intended. There can be no assurance that such data will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These advanced statements are made as of the date hereof and the ship’s company does not assume any obligation to update or revise them to reflect newfangled events or circumstances save as required under applicable securities legislation.
img 628455e445bd0

reservoir : https://aricantisp.com
Category : Accessories

Leave a Reply

Your email address will not be published.